History of lung transplantation G. Massard (Strasbourg, France)
| |
The key elements of a lung transplant programme P.A. Corris (Newcastle Upon Tyne, UK)
| |
Referral guidelines (general principles and specific issues in CF, ILD, COPD and PH) A. Boehler (Zurich, Switzerland)
| |
Candidate selection: specific controversial issues (previous malignancies and chronic infections) P.A. Corris (Newcastle Upon Tyne, UK)
| |
Pre-surgical management of lung transplant candidates (from clinical to psychological approaches) J. Gottlieb (Hanover, Germany)
| |
Lung transplant bridge with extracorporeal devices (ECMO and Novalung) M. Strüber (Hanover, Germany)
| |
Mechanical ventilation in lung transplant recipients D.E. Van Raemdonck (Leuven, Belgium)
| |
Identifying usable donor organs : pushing the boundaries G. Massard (Strasbourg, France)
| |
Non heart beating donors: principles, regulations, ethical issues, and results E.M.A. Verschuuren (Groningen, The Netherlands)
| |
Which donor features can affect graft outcome? E.M.A. Verschuuren (Groningen, The Netherlands)
| |
Increasing donation rates: lessons within Europe P. Thomas (Marseille, France)
| |
Ex vivo donor lung perfusion A. Fisher (Newcastle Upon Tyne, UK)
| |
How to perform a lung transplant G. Massard (Strasbourg, France)
| |
Pathophysiology and classification of PGD D.E. Van Raemdonck (Leuven, Belgium)
| |
New perspectives in PGD prevention and treatment J. Gottlieb (Hanover, Germany)
| |
Management of post-transplant airway complications G. Massard (Strasbourg, France)
| |
Acute cellular and humoral rejection F. Meloni (Pavia, Italy)
| |
Bronchoscopic monitoring after lung transplantation: actual role of TBB and BAL A. Boehler (Zurich, Switzerland)
| |
Challenges in post transplant lung pathology J. Gottlieb (Hanover, Germany)
| |
Hot Topics in Transplant Ethics P.A. Corris (Newcastle Upon Tyne, UK)
| |
Old and new strategies in induction therapy A. Boehler (Zurich, Switzerland)
| |
Calcineurin inhibitors: friend and foe? M. Iversen (Copenhagen, Denmark)
| |
Newer immunosuppressants: MMF and mTor inhibitors P.A. Corris (Newcastle Upon Tyne, UK)
| |
Actual role of azithromycin: when and how G.M. Verleden (Leuven, Belgium)
| |
CMV management in lung transplant recipients E.M.A. Verschuuren (Groningen, The Netherlands)
| |
Respiratory viral infections F. Meloni (Pavia, Italy)
| |
Aspergillus and other fungi G.M. Verleden (Leuven, Belgium)
| |
Multiresistant bacterial infections A. Fisher (Newcastle Upon Tyne, UK)
| |
1st successful lung TX in Szczecin, Poland B. Kubisa, (Szczecin, Poland)
| |
BOS/OB: aetiology and pathogenesis M. Iversen (Copenhagen, Denmark)
| |
BOS sub-phenotyping: beyond lung function G.M. Verleden (Leuven, Belgium)
| |
Diagnosing and managing BOS/OB A. Fisher (Newcastle Upon Tyne, UK)
| |
Old and new therapeutic options in BOS A. Boehler (Zurich, Switzerland)
| |
Retransplantation for graft failure: indications, outcomes and ethical issues G. Massard (Strasbourg, France)
| |
Assessemnt and treatment of GER F. Meloni (Pavia, Italy)
| |
Renal dysfunction and cardiovascular disorders M. Iversen (Copenhagen, Denmark)
| |
Lymphoproliferative disease: prevention and management E.M.A. Verschuuren (Groningen, The Netherlands)
| |
Other malignancies: prevention and treatment F. Meloni (Pavia, Italy)
| |